Semple, RK;
Vanhaesebroeck, B;
(2018)
Cancer drug tackles overgrowth syndrome.
Nature
, 558
(7711)
pp. 522-525.
Preview |
Text
Vanhaesebroeck_NVonCanaudedited_for upload.pdf - Accepted Version Download (641kB) | Preview |
Abstract
Abnormal activity of the enzyme PI3K can drive cancer growth, and mutations in a PI3K subunit can sometimes lead to non-cancerous overgrowth. A cancer drug that inhibits PI3K dramatically reduces such overgrowth.
| Type: | Article |
|---|---|
| Title: | Cancer drug tackles overgrowth syndrome |
| Open access status: | An open access version is available from UCL Discovery |
| Publisher version: | https://rdcu.be/1SXW |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10057246 |
Downloads since deposit
29Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months
Archive Staff Only
 |
View Item |
